Mediwound Ltd: Unternehmensprofil, Finanzberichte & Marktperformance

mehr Informationen über Mediwound Ltd Unternehmen

Mediwound Ltd is an Israel-based biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, which is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues.; EscharEx biological drug candidate for the debridement of chronic and other hard-to-heal wounds; MW005 a topically applied biological drug candidate for the treatment of non-melanoma skin cancers, based on the same API of NexoBrid and EscharEx products, a concentrate of proteolytic enzymes enriched in bromelain.

Mediwound Ltd Informationen



BörsenkürzelMDWD

Name des UnternehmensMediwound Ltd

IPO-datumMar 20, 2014

CEOMr. Ofer Gonen

Anzahl der mitarbeiter111

WertpapierartOrdinary Share

GeschäftsjahresendeMar 20

Addresse42 Hayarkon Street

StadtYAVNE

BörseNASDAQ Global Market Consolidated

LandIsrael

Postleitzahl8122745

Telefon972779714100

Websitehttps://www.mediwound.com/

BörsenkürzelMDWD

IPO-datumMar 20, 2014

CEOMr. Ofer Gonen

Führungskräfte von Mediwound Ltd



Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. Ofer Gonen

Chief Executive Officer, Director

182.10K

+84.44%

Mr. Nachum (Homi) Shamir

Independent Chairman of the Board

--

Mr. Jeremy Feffer

Managing Director

--

Ms. Hani Luxenburg

Chief Financial Officer

--

Mr. Stephen T. Wills, CPA

Independent Director

--

Dr. Ety Klinger, Ph.D.

Chief Research and Development Officer

--

Dr. Shmulik Hess

Chief Operating Officer, Chief Commercial Officer

--

Dr. Robert J. Snyder

Chief Medical Officer

--

Mr. David Fox

Independent Director

--

Dr. Vickie R. Driver, M.D.

Independent Director

--

Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. Ofer Gonen

Chief Executive Officer, Director

182.10K

+84.44%

Mr. Nachum (Homi) Shamir

Independent Chairman of the Board

--

Mr. Jeremy Feffer

Managing Director

--

Ms. Hani Luxenburg

Chief Financial Officer

--

Mr. Stephen T. Wills, CPA

Independent Director

--

Dr. Ety Klinger, Ph.D.

Chief Research and Development Officer

--

Umsatzaufteilung

Währung: USDAktualisiert: Mon, Oct 6

FY2024

FY2023

FY2022

FY2021

FY2020

Keine Daten

Nach RegionUSD

Name

Umsatz

Anteil

USA

15.46M

76.47%

EU and other international markets

4.76M

23.53%

Nach Geschäftsbereich

Nach Region

Keine Daten

Aktionärsstatistik

Aktualisiert: 10 hours ago

Aktionäre

Aktionärstypen

Aktionäre

Anteil

Clal Biotechnology Industries Ltd

11.55%

Investor AB

6.80%

Yelin Lapidot Provident Funds Management Ltd

6.32%

HOLD Alapkezelo Zrt

5.49%

Rosalind Advisors, Inc.

3.17%

Andere

66.66%

Aktionäre

Anteil

Clal Biotechnology Industries Ltd

11.55%

Investor AB

6.80%

Yelin Lapidot Provident Funds Management Ltd

6.32%

HOLD Alapkezelo Zrt

5.49%

Rosalind Advisors, Inc.

3.17%

Andere

66.66%

Aktionärstypen

Aktionäre

Anteil

Investment Advisor

20.75%

Holding Company

11.55%

Investment Advisor/Hedge Fund

9.39%

Private Equity

6.80%

Hedge Fund

4.93%

Venture Capital

2.95%

Corporation

2.17%

Individual Investor

1.42%

Research Firm

0.37%

Andere

39.66%

Institutionelle Beteiligung



Aktualisiert: Wed, Oct 1

Berichtszeitraum

Anzahl der Institutionen

Gehaltenen Aktien

Anteil

Veränderung

2025Q3

134

5.86M

45.68%

+524.92K

2025Q2

127

6.70M

61.97%

-1.10M

2025Q1

129

6.76M

62.72%

-1.01M

2024Q4

118

7.26M

67.33%

+161.02K

2024Q3

115

7.34M

70.49%

+440.76K

2024Q2

91

5.75M

66.40%

+288.97K

2024Q1

69

5.35M

61.63%

-376.56K

2023Q4

61

5.55M

64.63%

+32.10K

2023Q3

62

5.26M

71.22%

+1.01M

2023Q2

64

5.23M

72.67%

+954.42K

Aktionärsaktivitäten



Name

Gehaltenen Aktien

Anteil

Veränderung

Änderung%

Datum

Clal Biotechnology Industries Ltd

1.48M

11.55%

--

Sep 30, 2025

Investor AB

872.09K

6.8%

--

Jun 30, 2025

Yelin Lapidot Provident Funds Management Ltd

816.74K

6.37%

-41.26K

-4.81%

Jun 30, 2025

HOLD Alapkezelo Zrt

703.43K

5.49%

+703.43K

--

Sep 22, 2025

Rosalind Advisors, Inc.

407.06K

3.17%

-99.83K

-19.69%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

388.27K

3.03%

-45.72K

-10.54%

Jun 30, 2025

Israel Biotech Fund

378.62K

2.95%

-172.63K

-31.32%

Mar 15, 2025

T. Rowe Price Associates, Inc.

369.08K

2.88%

+214.12K

+138.19%

Jun 30, 2025

Deep Insight Limited Partnership

278.18K

2.17%

-273.07K

-49.54%

Mar 15, 2025

Verbundene ETFs



Aktualisiert: Thu, Nov 6

Name

Anteil

ARK Israel Innovative Technology ETF

1.45%

Invesco NASDAQ Future Gen 200 ETF

0.52%

iShares Micro-Cap ETF

0.03%

iShares Russell 2000 Growth ETF

0.01%

Global X Russell 2000 ETF

0%

ProShares Hedge Replication ETF

0%

iShares Russell 2000 ETF

0%

Proshares Ultra Russell 2000

0%

ProShares UltraPro Russell2000

0%

ARK Israel Innovative Technology ETF

Anteil1.45%

Invesco NASDAQ Future Gen 200 ETF

Anteil0.52%

iShares Micro-Cap ETF

Anteil0.03%

iShares Russell 2000 Growth ETF

Anteil0.01%

Global X Russell 2000 ETF

Anteil0%

ProShares Hedge Replication ETF

Anteil0%

iShares Russell 2000 ETF

Anteil0%

Proshares Ultra Russell 2000

Anteil0%

ProShares UltraPro Russell2000

Anteil0%

Dividende



In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.

Datum

Dividende

Stichtag für die Aktienregistrierung

Zahltag

Ex-Dividendentag

Keine Daten

Aktien-Split



Datum

Art

Verhältnis

Dec 19, 2022

Merger

7→1

Dec 19, 2022

Merger

7→1

Dec 19, 2022

Merger

7→1

Dec 19, 2022

Merger

7→1

Datum

Art

Verhältnis

Dec 19, 2022

Merger

7→1

Dec 19, 2022

Merger

7→1

Dec 19, 2022

Merger

7→1

Dec 19, 2022

Merger

7→1